Eto-GRY® 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Medical University Of Vienna, Universitaet Des Saarlandes

Conditions

Non-small cell lung cancerependymoma and atypical teratoid rhabdoid tumor (ATRT)extensive stage small cell lung cancer (SCLC)rare CNS tumorsrecurrent/progressive medulloblastoma

Phase 2

MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors

RecruitingCTIS2024-515626-92-00

Medical University Of Viennaependymoma and atypical teratoid rhabdoid tumor (ATRT), rare CNS tumors, recurrent/progressive medulloblastoma

Start: 2013-10-18Target: 100Updated: 2025-11-28

Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC

Not yet recruitingCTIS2024-517937-41-00

Universitaet Des Saarlandesextensive stage small cell lung cancer (SCLC)

Target: 43Updated: 2025-10-06

Phase 3

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)

RecruitingCTIS2022-502752-31-00

Merck Sharp & Dohme LLCNon-small cell lung cancer

Start: 2022-04-29Target: 68Updated: 2025-12-11